Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Isaac Kim
BMC Urology
View PDFchevron_right
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Andrew Protheroe
The New England journal of medicine, 2015
View PDFchevron_right
Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
nina tunariu
Cancer discovery, 2017
View PDFchevron_right
Prostate cancer and PARP inhibitors: progress and challenges
Nam Vuong
Journal of Hematology & Oncology
View PDFchevron_right
Molecular biomarkers to guide precision medicine in localized prostate cancer
Niven Mehra
Expert Review of Molecular Diagnostics
View PDFchevron_right
Defective DNA repair mechanisms in prostate cancer: impact of olaparib
Vincenzo Tombolini
Drug Design, Development and Therapy, 2017
View PDFchevron_right
PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review
Yann NEUZILLET
Prostate Cancer and Prostatic Diseases, 2020
View PDFchevron_right
How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients
Alessandro Sciarra
International Journal of Molecular Sciences
View PDFchevron_right
Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?
Alessandro Sciarra
Current Oncology
View PDFchevron_right
Targeting DNA repair in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Genomic Screening for a Clinical Trial of Rucaparib
Mitchell Gross
2019
View PDFchevron_right
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Tinaye Mutetwa
New England Journal of Medicine, 2020
View PDFchevron_right
Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer
Dylan Nelson
Clinical Cancer Research, 2014
View PDFchevron_right
PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCA
William Figg
The Oncologist, 2020
View PDFchevron_right
Clinical Applications of Molecular Biomarkers in Prostate Cancer
José López Torrecilla
Cancers, 2020
View PDFchevron_right
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
nina tunariu
The Lancet Oncology
View PDFchevron_right
Genomics of Prostate Cancer: Clinical Utility and Challenges
Ana Frobe
Acta Clinica Croatica, 2022
View PDFchevron_right
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA
Ernesto Korbenfeld
Clinical Cancer Research
View PDFchevron_right
DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries
Marc-antoine BENDERRA
The Prostate
View PDFchevron_right
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer
Albert Holler
JCO Precision Oncology
View PDFchevron_right
Changing the History of Prostate Cancer with New Targeted Therapies
Susana Hernando Polo
Biomedicines, 2021
View PDFchevron_right
Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer
Brian Abbey
Current Treatment Options in Oncology
View PDFchevron_right
Abstract 445: Genomic characteristics and response to rucaparib and enzalutamide in the phase 1b RAMP study of metastatic castration-resistant prostate cancer (mCRPC) patients
Gautam Jha
2021
View PDFchevron_right
Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
George Pappas-Gogos
International Journal of Molecular Sciences
View PDFchevron_right
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
Winston Tan
EBioMedicine
View PDFchevron_right
Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection
Alexis LeVee
OncoTargets and Therapy, 2021
View PDFchevron_right
Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer
seng thao
Scientific Reports, 2022
View PDFchevron_right